Modern medicine can be remarkably precise about what happens inside the body, yet much of what shapes recovery happens outside the pill. Movement, cognition, behavior and daily routines can influence how patients manage chronic disease, but those interventions often sit in separate programs, appointments and apps. Remepy is building around a different idea: what if part of that care traveled with the medicine itself?
The New York clinical-stage biotech calls the model Hybrid Drugs. Each treatment combines two components: a pharmaceutical molecule targeting biological pathways and an adaptive digital protocol delivering physical, cognitive, and behavioral interventions. Remepy says the software can personalize those interventions using patient data and daily fluctuations, creating a treatment that continues engaging with the patient after the dose is taken. In that model, the pill bottle stops being the boundary of the prescription.
Remepy has now raised $36 million in Series A funding, co-led by O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, Darmstadt, Germany. NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital and IT-Farm also participated. The financing brings total capital raised to $62 million.
Co-CEOs Michal Tsur and Or Shoval are putting that thesis through its most important clinical test with Hybridopa, Remepy’s investigational Parkinson’s program. Hybridopa combines levodopa-based treatment with DopApp, a digital protocol designed to deliver multidisciplinary care at home. Remepy’s Phase IIa study enrolled 41 patients and reported a mean 9.7-point reduction in MDS-UPDRS Parts I+II+III, compared with 1.95 points in the control group. Researchers also reported functional-connectivity changes associated with motor and mood improvements. The study was small, and Hybridopa remains investigational and unapproved.
The next test will be much larger. Remepy says the new financing will support a global Phase III program scheduled to begin in Q4 2026, while expanding its Hybrid Drug platform and pharmaceutical co-development partnerships. The latest funding announcement should be treated as the current timing source, since another Remepy product page still lists Q3 2026.
The platform is already moving beyond Parkinson’s. Remepy has a collaboration with Merck KGaA spanning multiple potential indications, initially focused on rare tumors, while its website also lists oncology and women’s health among its development areas.
That broader pipeline matters because Remepy is pitching Hybrid Drugs as a pharmaceutical model, not simply a digital-health product. The company argues that pairing medicines with software could create additional intellectual property, differentiate existing and future drugs, support lifecycle management and potentially improve development outcomes through more personalized treatment. Those commercial benefits remain Remepy’s thesis rather than proven outcomes.
Phase III will therefore test more than one Parkinson’s program. It will test whether software can move from sitting beside medicine to becoming part of how medicine itself is designed, delivered and differentiated.